NASDAQ:BIOL - Biolase Stock Price, Price Target & More

$0.35 -0.02 (-5.41 %)
(As of 04/26/2018 03:18 PM ET)
Previous Close$0.37
Today's Range$0.34 - $0.38
52-Week Range$0.28 - $1.45
Volume194,783 shs
Average Volume154,879 shs
Market Capitalization$35.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72

About Biolase (NASDAQ:BIOL)

Biolase logoBIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine in the United States and internationally. The company offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. Its dental imaging products comprise 3Shape Trios intraoral scanner and digital impression systems for high-speed digital 3-D picture taking; Galaxy BioMill CAD/CAM system that enables dental practitioners to design, scan, mill, and finish crowns, inlays, and veneers inside the dental office; and CEFLA NewTom VGi and VG3 3-D cone beam computed tomography devices. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOL
CUSIPN/A
Phone949-361-1200

Debt

Debt-to-Equity RatioN/A
Current Ratio2.70%
Quick Ratio1.78%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$46.93 million
Price / Sales0.76
Cash FlowN/A
Price / CashN/A
Book Value$0.29 per share
Price / Book1.21

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-16,850,000.00
Net Margins-35.91%
Return on Equity-67.04%
Return on Assets-39.50%

Miscellaneous

Employees195
Outstanding Shares102,350,000

How to Become a New Pot Stock Millionaire

Biolase (NASDAQ:BIOL) Frequently Asked Questions

What is Biolase's stock symbol?

Biolase trades on the NASDAQ under the ticker symbol "BIOL."

How were Biolase's earnings last quarter?

Biolase (NASDAQ:BIOL) issued its quarterly earnings data on Wednesday, March, 14th. The medical technology company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.04). The medical technology company earned $12.63 million during the quarter. Biolase had a negative return on equity of 67.04% and a negative net margin of 35.91%. View Biolase's Earnings History.

When is Biolase's next earnings date?

Biolase is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Biolase.

Who are some of Biolase's key competitors?

Who are Biolase's key executives?

Biolase's management team includes the folowing people:
  • Mr. Harold C. Flynn Jr., CEO, Pres & Director (Age 53)
  • Mr. Dmitri Boutoussov Ph.D., VP of R&D (Age 55)
  • Mr. John R. Beaver, Sr. VP, CFO & Principal Accounting Officer (Age 57)
  • Mr. Richard R. Whipp, VP of Operations (Age 66)
  • Mr. William E. Brown Jr., VP of Bus. Devel. (Age 70)

Has Biolase been receiving favorable news coverage?

News articles about BIOL stock have been trending positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biolase earned a coverage optimism score of 0.37 on Accern's scale. They also gave media stories about the medical technology company an impact score of 48.08 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Biolase?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biolase's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.35.

How big of a company is Biolase?

Biolase has a market capitalization of $35.63 million and generates $46.93 million in revenue each year. Biolase employs 195 workers across the globe.

How can I contact Biolase?

Biolase's mailing address is 4 CROMWELL, IRVINE CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]


MarketBeat Community Rating for Biolase (BIOL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  255
MarketBeat's community ratings are surveys of what our community members think about Biolase and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biolase (NASDAQ:BIOL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/ABuyBuyBuy
Consensus Rating Score: N/A3.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$2.50$2.50$2.50
Price Target Upside: N/A96.85% upside96.85% upside96.85% upside

Biolase (NASDAQ:BIOL) Consensus Price Target History

Price Target History for Biolase (NASDAQ:BIOL)

Biolase (NASDAQ:BIOL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/25/2017Singular ResearchInitiated CoverageBuy$2.50LowView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Biolase (NASDAQ:BIOL) Earnings History and Estimates Chart

Earnings by Quarter for Biolase (NASDAQ:BIOL)

Biolase (NASDAQ BIOL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($0.04)N/AView Earnings Details
3/14/2018Q4 2017($0.04)($0.04)$12.63 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.06)$10.81 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.02)($0.06)$12.61 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.03)($0.06)$10.87 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.02($0.06)$13.76 millionViewListenView Earnings Details
11/8/2016Q316($0.02)($0.05)$12.40 million$13.20 millionViewListenView Earnings Details
8/1/2016Q2 2016($0.05)$13.81 millionViewN/AView Earnings Details
5/9/2016Q116($0.03)($0.07)$11.90 million$11.00 millionViewN/AView Earnings Details
3/9/2016Q415($0.09)($0.04)$13.90 million$14.50 millionViewN/AView Earnings Details
11/4/2015Q315($0.08)($0.09)$1.50 million$11.20 millionViewN/AView Earnings Details
8/5/2015Q2 2015($0.12)$11.87 millionViewN/AView Earnings Details
4/30/2015Q1 2015($0.09)$10.86 millionViewN/AView Earnings Details
3/4/2015Q4 2014($0.07)$13.24 millionViewN/AView Earnings Details
11/4/2014Q314($0.09)($0.08)$11.70 million$12.70 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.17)$12.97 million$10.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.11)$13.29 million$11.50 millionViewN/AView Earnings Details
3/5/2014Q413($0.04)($0.04)$15.67 million$15.20 millionViewN/AView Earnings Details
11/5/2013Q313($0.05)($0.10)$16.42 million$12.30 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.04)($0.06)$15.69 million$14.20 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.06)$14.48 million$14.60 millionViewN/AView Earnings Details
3/6/2013Q4 2012$0.05$18.03 million$19.10 millionViewListenView Earnings Details
11/5/2012Q3 2012($0.02)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.06)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.05)ViewN/AView Earnings Details
3/8/2012Q4 2011($0.03)($0.06)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.01)($0.03)ViewN/AView Earnings Details
8/10/2011Q2 2011$0.04($0.03)ViewN/AView Earnings Details
5/9/2011Q1 2011$0.02($0.02)ViewN/AView Earnings Details
3/10/2011Q4 2010$0.01$0.01ViewN/AView Earnings Details
11/2/2010Q3 2010($0.08)($0.10)ViewN/AView Earnings Details
8/17/2010Q2 2010($0.11)($0.16)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.08)($0.20)ViewN/AView Earnings Details
3/18/2010Q4 2009$0.09($0.06)ViewN/AView Earnings Details
11/5/2009Q3 2009$0.03$0.05ViewN/AView Earnings Details
8/6/2009Q2 2009$0.09ViewN/AView Earnings Details
5/7/2009Q1 2009($0.18)ViewN/AView Earnings Details
3/16/2009Q4 2008($0.06)($0.19)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.06)($0.17)ViewN/AView Earnings Details
8/7/2008Q2 2008$0.01$0.02ViewN/AView Earnings Details
3/11/2008Q4 2007($0.01)($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Biolase (NASDAQ:BIOL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Biolase (NASDAQ BIOL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 36.18%
Insider Trading History for Biolase (NASDAQ:BIOL)
Institutional Ownership by Quarter for Biolase (NASDAQ:BIOL)

Biolase (NASDAQ BIOL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2017Larry N FeinbergMajor ShareholderBuy12,545,615$0.43$5,394,614.45View SEC Filing  
2/18/2016Jack W SchulerMajor ShareholderBuy500$0.80$400.00View SEC Filing  
2/17/2016Jack W SchulerMajor ShareholderBuy4,100$0.80$3,280.00View SEC Filing  
2/12/2016Jack W SchulerMajor ShareholderBuy19,080$0.76$14,500.80View SEC Filing  
2/10/2016Jack W SchulerMajor ShareholderBuy67,213$0.78$52,426.14View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy1,400$0.80$1,120.00View SEC Filing  
1/22/2016Jack W SchulerMajor ShareholderBuy6,670$0.78$5,202.60View SEC Filing  
1/20/2016Jack W SchulerMajor ShareholderBuy24,200$0.75$18,150.00View SEC Filing  
12/28/2015Jack W SchulerMajor ShareholderBuy18,350$0.79$14,496.50View SEC Filing  
12/24/2015Jack W SchulerMajor ShareholderBuy41,900$0.76$31,844.00View SEC Filing  
12/22/2015Jack W SchulerMajor ShareholderBuy87,200$0.74$64,528.00View SEC Filing  
12/21/2015Jack W SchulerMajor ShareholderBuy127,892$0.73$93,361.16View SEC Filing  
12/17/2015Jack W SchulerMajor ShareholderBuy34,158$0.70$23,910.60View SEC Filing  
11/11/2015Larry N FeinbergMajor ShareholderBuy54,800$0.79$43,292.00View SEC Filing  
11/10/2015Paul N ClarkDirectorBuy134,579$0.75$100,934.25View SEC Filing  
9/24/2015David C DreyerCFOBuy5,000$1.20$6,000.0020,000View SEC Filing  
9/22/2015David C DreyerCFOBuy5,000$1.37$6,850.0015,000View SEC Filing  
9/17/2015David C DreyerCFOBuy10,000$1.45$14,500.0010,000View SEC Filing  
11/3/2014Jeffrey M NugentCEOBuy40,465$2.39$96,711.35View SEC Filing  
11/3/2014Jonathan T Md LordDirectorBuy101,163$2.39$241,779.57View SEC Filing  
11/3/2014Larry N FeinbergMajor ShareholderBuy2,067,979$2.39$4,942,469.81View SEC Filing  
7/22/2014Alexander K ArrowCOOBuy7,812$1.92$14,999.04View SEC Filing  
7/22/2014Frederick D FurryCFOBuy13,020$1.92$24,998.40View SEC Filing  
7/22/2014Jeffrey M NugentCEOBuy52,083$1.92$99,999.36View SEC Filing  
7/22/2014Paul N ClarkDirectorBuy520,833$1.92$999,999.36View SEC Filing  
7/18/2014Larry N FeinbergMajor ShareholderBuy2,270,836$1.92$4,360,005.12View SEC Filing  
2/12/2014Larry N FeinbergMajor ShareholderBuy2,035,033$2.57$5,230,034.81View SEC Filing  
1/31/2014Larry Feinbergmajor shareholderBuy30,798$2.45$75,455.10View SEC Filing  
12/19/2013Larry Feinbergmajor shareholderBuy340,000$1.80$612,000.00View SEC Filing  
12/17/2013Larry Feinbergmajor shareholderBuy150,400$1.87$281,248.00View SEC Filing  
8/23/2012Frederick D FurryCFOBuy5,075$1.64$8,323.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biolase (NASDAQ BIOL) News Headlines

Source:
DateHeadline
BIOLASE® To Host 2018 First Quarter Financial Results Conference Call On May 2, 2018BIOLASE® To Host 2018 First Quarter Financial Results Conference Call On May 2, 2018
finance.yahoo.com - April 25 at 9:45 AM
Biolase (BIOL) to Release Quarterly Earnings on TuesdayBiolase (BIOL) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 8:24 AM
Contrasting Biolase (BIOL) & Sartorius (SARTF)Contrasting Biolase (BIOL) & Sartorius (SARTF)
www.americanbankingnews.com - April 19 at 9:08 PM
Biolase (BIOL) & Straumann (SAUHF) Critical ReviewBiolase (BIOL) & Straumann (SAUHF) Critical Review
www.americanbankingnews.com - April 19 at 9:06 PM
BIOLASE Establishes Southern California Dental Advisory BoardBIOLASE Establishes Southern California Dental Advisory Board
finance.yahoo.com - April 17 at 9:56 AM
Biolase (BIOL) Stock Rating Lowered by ValuEngineBiolase (BIOL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 16 at 7:35 PM
Head-To-Head Analysis: Dentsply Sirona (XRAY) versus Biolase (BIOL)Head-To-Head Analysis: Dentsply Sirona (XRAY) versus Biolase (BIOL)
www.americanbankingnews.com - April 16 at 1:35 AM
Head-To-Head Comparison: Biolase (BIOL) & Dentsply Sirona (XRAY)Head-To-Head Comparison: Biolase (BIOL) & Dentsply Sirona (XRAY)
www.americanbankingnews.com - April 12 at 1:17 AM
Sartorius (SARTF) vs. Biolase (BIOL) Head to Head SurveySartorius (SARTF) vs. Biolase (BIOL) Head to Head Survey
www.americanbankingnews.com - April 11 at 7:35 PM
BIOLASE to explore strategic alternatives, CEO resignsBIOLASE to explore strategic alternatives, CEO resigns
seekingalpha.com - April 11 at 10:18 AM
BRIEF-Biolase Has Asked Jonathan Lord Chairman Of Board Of Biolase, To Lead Cos Exploration Of Strategic AlternativesBRIEF-Biolase Has Asked Jonathan Lord Chairman Of Board Of Biolase, To Lead Co's Exploration Of Strategic Alternatives
www.reuters.com - April 11 at 10:18 AM
BIOLASE Board Of Directors Asks Chairman Jonathan T. Lord, M.D. To Take On Expanded Leadership Role And Explore Strategic OptionsBIOLASE Board Of Directors Asks Chairman Jonathan T. Lord, M.D. To Take On Expanded Leadership Role And Explore Strategic Options
finance.yahoo.com - April 11 at 10:18 AM
Biolase (BIOL) Upgraded to Hold by ValuEngineBiolase (BIOL) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - April 8 at 1:29 PM
Sartorius (SARTF) & BIOLASE (BIOL) Critical SurveySartorius (SARTF) & BIOLASE (BIOL) Critical Survey
www.americanbankingnews.com - April 5 at 10:11 AM
BIOLASE Names Garrett Sato To Board Of DirectorsBIOLASE Names Garrett Sato To Board Of Directors
finance.yahoo.com - April 4 at 5:11 PM
BIOLASE Announces Growing Awareness of Dental Lasers Among Pediatric Dentists, Demonstrating Shift Toward Pain-Free DentistryBIOLASE Announces Growing Awareness of Dental Lasers Among Pediatric Dentists, Demonstrating Shift Toward Pain-Free Dentistry
finance.yahoo.com - March 28 at 9:53 AM
Head-To-Head Comparison: Henry Schein (HSIC) & BIOLASE (BIOL)Head-To-Head Comparison: Henry Schein (HSIC) & BIOLASE (BIOL)
www.americanbankingnews.com - March 26 at 11:27 PM
Edited Transcript of BIOL earnings conference call or presentation 14-Mar-18 8:30pm GMTEdited Transcript of BIOL earnings conference call or presentation 14-Mar-18 8:30pm GMT
finance.yahoo.com - March 18 at 9:32 AM
BIOLASE (BIOL) Releases Quarterly  Earnings Results, Hits ExpectationsBIOLASE (BIOL) Releases Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - March 15 at 7:56 AM
BIOLASE, Inc. to Host Earnings CallBIOLASE, Inc. to Host Earnings Call
www.baystreet.ca - March 14 at 5:31 PM
BIOLASE Reports 2017 Fourth Quarter And Full-Year ResultsBIOLASE Reports 2017 Fourth Quarter And Full-Year Results
www.bizjournals.com - March 14 at 5:31 PM
Is It Too Late To Buy BIOLASE Inc (NASDAQ:BIOL)?Is It Too Late To Buy BIOLASE Inc (NASDAQ:BIOL)?
finance.yahoo.com - March 14 at 10:42 AM
BIOLASE (BIOL) Set to Announce Earnings on WednesdayBIOLASE (BIOL) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 8:20 PM
BIOLASE Secures $6 Million Revolving Line Of CreditBIOLASE Secures $6 Million Revolving Line Of Credit
finance.yahoo.com - March 7 at 9:44 AM
BIOLASE® To Host 2017 Fourth Quarter Financial Results Conference Call On March 14, 2018BIOLASE® To Host 2017 Fourth Quarter Financial Results Conference Call On March 14, 2018
finance.yahoo.com - March 6 at 9:28 AM
Biolase (BIOL) Announces MOU With S-Ray to Market, Sell Disruptive Radiation-Free Dental Imaging DeviceBiolase (BIOL) Announces MOU With S-Ray to Market, Sell Disruptive Radiation-Free Dental Imaging Device
www.streetinsider.com - February 28 at 9:32 AM
BIOLASE Announces Memorandum Of Understanding With S-Ray To Market, Sell Disruptive Radiation-Free Dental Imaging DeviceBIOLASE Announces Memorandum Of Understanding With S-Ray To Market, Sell Disruptive Radiation-Free Dental Imaging Device
finance.yahoo.com - February 27 at 9:37 AM
BIOLASE (BIOL) Set to Announce Earnings on TuesdayBIOLASE (BIOL) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:16 AM
Dynatronics (DYNT) Reports Separation of Chairmanship and CEO Positions; Chairman and CEO Kelvyn Cullimore to Step DownDynatronics (DYNT) Reports Separation of Chairmanship and CEO Positions; Chairman and CEO Kelvyn Cullimore to Step Down
www.streetinsider.com - February 23 at 4:47 PM
BIOLASE Announces Initiatives to Increase Dental Laser Awareness and Education in Southern CaliforniaBIOLASE Announces Initiatives to Increase Dental Laser Awareness and Education in Southern California
finance.yahoo.com - February 15 at 8:51 AM
Nasdaq Grants BIOLASE 180-Day Extension To Meet Minimum Bid Price RequirementNasdaq Grants BIOLASE 180-Day Extension To Meet Minimum Bid Price Requirement
finance.yahoo.com - February 7 at 9:06 AM
BRIEF-CAO Group Filed Patent Infringement Lawsuits In Court Against BiolaseBRIEF-CAO Group Filed Patent Infringement Lawsuits In Court Against Biolase
www.reuters.com - January 24 at 4:52 PM
CAO Group, Inc. Protects Its Diode Laser Patent Rights From Infringement By Biolase, Inc.CAO Group, Inc. Protects Its Diode Laser Patent Rights From Infringement By Biolase, Inc.
finance.yahoo.com - January 24 at 4:52 PM
BRIEF-Biolase Files For Possible Resale Of Up To 21.9 Mln Shares Of Common Stock By Selling StockholdersBRIEF-Biolase Files For Possible Resale Of Up To 21.9 Mln Shares Of Common Stock By Selling Stockholders
www.reuters.com - January 16 at 5:38 PM
BIOLASE Receives Awards From Leading Industry Organizations ... - PR Newswire (press release)BIOLASE Receives Awards From Leading Industry Organizations ... - PR Newswire (press release)
www.prnewswire.com - January 5 at 3:47 PM
BIOLASE Receives Awards From Leading Industry Organizations For Its Dental Laser SystemsBIOLASE Receives Awards From Leading Industry Organizations For Its Dental Laser Systems
finance.yahoo.com - January 4 at 9:05 AM
Critical Contrast: Biolase (BIOL) & ArthroCare (ARTC)Critical Contrast: Biolase (BIOL) & ArthroCare (ARTC)
www.americanbankingnews.com - December 22 at 3:04 AM
ETFs with exposure to BIOLASE, Inc. : December 11, 2017ETFs with exposure to BIOLASE, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:43 PM
Critical Analysis: Mindray Medical International (MR) versus Biolase (BIOL)Critical Analysis: Mindray Medical International (MR) versus Biolase (BIOL)
www.americanbankingnews.com - December 7 at 3:32 AM
Biolase, Inc. (BIOL) Major Shareholder Larry N. Feinberg Purchases 12,545,615 SharesBiolase, Inc. (BIOL) Major Shareholder Larry N. Feinberg Purchases 12,545,615 Shares
www.americanbankingnews.com - December 6 at 5:22 PM
Zacks: Biolase, Inc. (BIOL) Given Average Rating of "Strong Buy" by AnalystsZacks: Biolase, Inc. (BIOL) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 2 at 11:30 PM
ETFs with exposure to BIOLASE, Inc. : December 1, 2017ETFs with exposure to BIOLASE, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 4:27 PM
BRIEF-BIOLASE Announces Expiration Of Rights OfferingBRIEF-BIOLASE Announces Expiration Of Rights Offering
www.reuters.com - November 30 at 3:44 PM
BIOLASE Announces Expiration of Rights OfferingBIOLASE Announces Expiration of Rights Offering
finance.yahoo.com - November 30 at 9:12 AM
Financial Comparison: Biolase (BIOL) and Synergetics USA (SURG)Financial Comparison: Biolase (BIOL) and Synergetics USA (SURG)
www.americanbankingnews.com - November 28 at 1:08 AM
BIOLASE to Conduct Demos of Portable Waterlase Express™ All-Tissue Laser System at Greater New York Dental MeetingBIOLASE to Conduct Demos of Portable Waterlase Express™ All-Tissue Laser System at Greater New York Dental Meeting
finance.yahoo.com - November 22 at 5:15 PM
ETFs with exposure to BIOLASE, Inc. : November 20, 2017ETFs with exposure to BIOLASE, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 3:23 PM
BIOLASE to Present at the LD Micro 10th Annual Main Event ConferenceBIOLASE to Present at the LD Micro 10th Annual Main Event Conference
finance.yahoo.com - November 17 at 8:42 AM
BIOLASE to Present at the Singular Research Best of the Uncovered 12th Annual Conference 2017BIOLASE to Present at the Singular Research Best of the Uncovered 12th Annual Conference 2017
finance.yahoo.com - November 16 at 9:33 AM
Biolase (BIOL) Commences Rights OfferingBiolase (BIOL) Commences Rights Offering
www.streetinsider.com - November 11 at 4:25 PM

SEC Filings

Biolase (NASDAQ:BIOL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biolase (NASDAQ:BIOL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biolase (NASDAQ BIOL) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.